ArticlePloS one2026
Effect of autologous platelet-rich plasma on optical quality and visual outcomes following implantation of a trifocal diffractive intraocular lens.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the effect of autologous platelet-rich plasma (PRP) eye drops on optical quality and visual acuity in eyes implanted with a trifocal diffractive intraocular lens (IOL).
methodsIn this retrospective cohort study of 128 eyes from 128 patients undergoing femtosecond laser-assisted cataract surgery with implantation of the CNWT Clareon PanOptix (Alcon Inc.) IOL, patients were assigned to one of two groups: the PRP group (n = 62), which received postoperative PRP eye drops, and the conventional treatment group (n = 66). At 3 weeks postoperatively, optical parameters-including the objective scatter index (OSI), modulation transfer function (MTF) cutoff, and Strehl ratio (SR)-were measured with a double-pass system. Uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA) at 4 m, as well as uncorrected near visual acuity (UNVA) at 40 cm, were recorded in logMAR units.
resultsThe PRP group demonstrated superior optical quality across all measured parameters compared to the control group, with lower OSI (1.60 vs. 3.14), higher MTF cutoff (31.93 vs. 19.90 cycles/degree), and higher SR (0.15 vs. 0.12) (all P < 0.001). Visual acuity was also significantly better in the PRP group, with lower mean logMAR UDVA (0.05 vs. 0.10; P < 0.001), CDVA (0.01 vs. 0.05; P < 0.001), and UNVA (0.13 vs. 0.18; P = 0.007). Multivariate analyses confirmed that the use of PRP eye drops was independently associated with improvements in all three optical parameters: OSI (B = -1.488), MTF cutoff (B = 12.038), and SR (B = 0.039) (all P < 0.001).
conclusionsThe use of autologous PRP eye drops improves optical quality and visual acuity at all distances following trifocal diffractive IOL implantation. PRP eye drops may serve as a beneficial adjunct for postoperative management in patients undergoing this procedure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.